Ceritinib (LDK378) is a selective, oral ALK inhibitor (IC50 = 200 pM) with additional activity against IGF-1R, InsR, and STK22D. It demonstrates strong antitumor potency. Reagent grade, for research use only.
Usually ships within 24 hours.